Organovo Holdings, Inc. is excited to announce its latest milestone in innovation and growth, having successfully raised $9,000,000 in new funding. This capital infusion reinforces our unwavering commitment to revolutionizing the landscape of drug discovery by harnessing our pioneering 3D bioprinting technology. At Organovo, we specialize in crafting tissues that mimic key aspects of human biology and disease, thereby offering a radically improved platform for therapeutic and drug profiling. This breakthrough technology allows us to generate human primary cell 3D models of disease that closely recapitulate disease processes, providing a robust and reliable framework for testing novel drug therapies with a higher chance of clinical success.
The funds raised will primarily be allocated towards advancing our core research and development initiatives. Specifically, we plan to expand our bioprinting capabilities, optimize our tissue engineering processes, and drive further preclinical studies that will underpin the development of next-generation therapies. In addition, a portion of the investment will be directed towards strengthening our manufacturing infrastructure and scaling our operations to meet the burgeoning demand for innovative drug discovery platforms. Our mission remains steadfast: to fundamentally alter the drug discovery paradigm by bridging the gap between laboratory innovation and clinical efficacy. We believe that by focusing on human-relevant disease models, we can transform therapeutic development, reduce costly drug failures, and accelerate the delivery of effective treatments to patients. To learn more about our revolutionary approach and cutting-edge technologies, visit our website at www.organovo.com. The future of drug discovery is here, and Organovo is leading the charge.
